{"transactions":[{"id":4625548,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-23T20:54:08.000Z","date":"2026-09-21","kind":"sale","planned":false,"acquired":false,"shares":87,"price":2.9742,"value":258.7554,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":11160,"source":{"system":"sec-edgar","filing":"0001609284-26-000005","document":"form4-09232026_080903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000160928426000005/form4-09232026_080903.xml","form_type":"4"}},{"id":4625545,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2026-09-23T20:52:41.000Z","date":"2026-09-21","kind":"sale","planned":false,"acquired":false,"shares":302,"price":2.9742,"value":898.2084,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":18500,"source":{"system":"sec-edgar","filing":"0001692747-26-000005","document":"form4-09232026_080937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000005/form4-09232026_080937.xml","form_type":"4"}},{"id":690496,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:43:58.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001193125-26-344874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526344874/ownership.xml","form_type":"4"}},{"id":690423,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:40:52.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001547100-26-000005","document":"form4-08112026_080842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000154710026000005/form4-08112026_080842.xml","form_type":"4"}},{"id":690300,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:54.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001921956-26-000003","document":"form4-08112026_080848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000192195626000003/form4-08112026_080848.xml","form_type":"4"}},{"id":690672,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:03.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001622769-26-000002","document":"form4-08112026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000002/form4-08112026_080858.xml","form_type":"4"}},{"id":690671,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:03.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001622769-26-000002","document":"form4-08112026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000002/form4-08112026_080858.xml","form_type":"4"}},{"id":690670,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:39:03.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 24, 2027 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":300000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001622769-26-000002","document":"form4-08112026_080858.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000002/form4-08112026_080858.xml","form_type":"4"}},{"id":690915,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24651,"kind":"person","name":"Jansen Valerie Malyvanh","position":1,"cik":"0001889716","reported_name":"Jansen Valerie Malyvanh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:37:33.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001889716-26-000002","document":"form4-08112026_080824.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1889716/000188971626000002/form4-08112026_080824.xml","form_type":"4"}},{"id":690509,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:36:20.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001240122-26-000006","document":"form4-08112026_080811.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240122/000124012226000006/form4-08112026_080811.xml","form_type":"4"}},{"id":690676,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24592,"kind":"person","name":"Carruthers R Michael","position":1,"cik":"0001644467","reported_name":"Carruthers R Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:31:17.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001644467-26-000002","document":"form4-08112026_080808.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644467/000164446726000002/form4-08112026_080808.xml","form_type":"4"}},{"id":690343,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":542232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":542232,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":542232},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690342,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":542232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":542232},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690341,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":16898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":16898,"derivative":{"exercise_price":4.14,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":16898},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690340,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":16898},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690339,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":8449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":8449,"derivative":{"exercise_price":4.14,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":8449},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690338,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":8449},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690337,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":1485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":1485,"derivative":{"exercise_price":4.14,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":1485},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690336,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":1485},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690335,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":2359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":2359,"derivative":{"exercise_price":4.14,"expiration_date":"2032-01-03","underlying":"Class A Common Stock","underlying_shares":2359},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690334,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":21.2,"expiration_date":"2032-01-10","underlying":"Class A Common Stock","underlying_shares":2359},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690333,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:27:49.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":150000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001609284-26-000004","document":"form4-08112026_080840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000004/form4-08112026_080840.xml","form_type":"4"}},{"id":690793,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:26:42.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":130611,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":130611,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":130611},"source":{"system":"sec-edgar","filing":"0001692747-26-000004","document":"form4-08112026_080837.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000004/form4-08112026_080837.xml","form_type":"4"}},{"id":690792,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:26:42.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":130611,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":130611},"source":{"system":"sec-edgar","filing":"0001692747-26-000004","document":"form4-08112026_080837.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000004/form4-08112026_080837.xml","form_type":"4"}},{"id":690791,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:26:42.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":5322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":5322,"derivative":{"exercise_price":4.14,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":5322},"source":{"system":"sec-edgar","filing":"0001692747-26-000004","document":"form4-08112026_080837.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000004/form4-08112026_080837.xml","form_type":"4"}},{"id":690790,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:26:42.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":5322},"source":{"system":"sec-edgar","filing":"0001692747-26-000004","document":"form4-08112026_080837.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000004/form4-08112026_080837.xml","form_type":"4"}},{"id":690789,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy","published_at":"2026-08-11T20:26:42.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":5781,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":5781,"derivative":{"exercise_price":4.14,"expiration_date":"2032-01-10","underlying":"Class A Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001692747-26-000004","document":"form4-08112026_080837.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000004/form4-08112026_080837.xml","form_type":"4"}},{"id":690788,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy","published_at":"2026-08-11T20:26:42.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5781,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":21.2,"expiration_date":"2032-01-10","underlying":"Class A Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001692747-26-000004","document":"form4-08112026_080837.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000004/form4-08112026_080837.xml","form_type":"4"}},{"id":690787,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:26:42.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":50000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001692747-26-000004","document":"form4-08112026_080837.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000004/form4-08112026_080837.xml","form_type":"4"}},{"id":690982,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24691,"kind":"person","name":"Hartley Dylan","position":1,"cik":"0002037442","reported_name":"Hartley Dylan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:25:32.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":137603,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option vested on June 9, 2025 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":137603,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":137603},"source":{"system":"sec-edgar","filing":"0002037442-26-000002","document":"form4-08112026_080827.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2037442/000203744226000002/form4-08112026_080827.xml","form_type":"4"}},{"id":690981,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24691,"kind":"person","name":"Hartley Dylan","position":1,"cik":"0002037442","reported_name":"Hartley Dylan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:25:32.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":137603,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option vested on June 9, 2025 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":137603},"source":{"system":"sec-edgar","filing":"0002037442-26-000002","document":"form4-08112026_080827.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2037442/000203744226000002/form4-08112026_080827.xml","form_type":"4"}},{"id":690980,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24691,"kind":"person","name":"Hartley Dylan","position":1,"cik":"0002037442","reported_name":"Hartley Dylan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:25:32.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":50000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0002037442-26-000002","document":"form4-08112026_080827.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037442/000203744226000002/form4-08112026_080827.xml","form_type":"4"}},{"id":690840,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":131396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":131396,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":131396},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690839,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":131396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":131396},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690838,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":18588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":18588,"derivative":{"exercise_price":4.14,"expiration_date":"2034-02-05","underlying":"Class A Common Stock","underlying_shares":18588},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690837,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2034-02-05","underlying":"Class A Common Stock","underlying_shares":18588},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690836,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":50000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":727410,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2026-06-24T23:29:18.000Z","date":"2026-06-22","kind":"sale","planned":false,"acquired":false,"shares":86,"price":4.3963,"value":378.0818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026."}],"balance_after":11247,"source":{"system":"sec-edgar","filing":"0001609284-26-000003","document":"form4-06242026_110612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000003/form4-06242026_110612.xml","form_type":"4"}},{"id":727650,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2026-06-24T23:27:44.000Z","date":"2026-06-22","kind":"sale","planned":false,"acquired":false,"shares":303,"price":4.3963,"value":1332.0789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026."}],"balance_after":18802,"source":{"system":"sec-edgar","filing":"0001692747-26-000003","document":"form4-06242026_110637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000003/form4-06242026_110637.xml","form_type":"4"}},{"id":745898,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:32:56.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001193125-26-262279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526262279/ownership.xml","form_type":"4"}},{"id":745835,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:27:29.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":1275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":1275,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":1275},"source":{"system":"sec-edgar","filing":"0001547100-26-000004","document":"form4-06082026_100623.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000154710026000004/form4-06082026_100623.xml","form_type":"4"}},{"id":745767,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:26:10.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001921956-26-000002","document":"form4-06082026_100605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000192195626000002/form4-06082026_100605.xml","form_type":"4"}},{"id":746451,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24651,"kind":"person","name":"Jansen Valerie Malyvanh","position":1,"cik":"0001889716","reported_name":"Jansen Valerie Malyvanh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:25:17.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001889716-26-000001","document":"form4-06082026_100613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1889716/000188971626000001/form4-06082026_100613.xml","form_type":"4"}},{"id":745989,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:24:32.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001240122-26-000003","document":"form4-06082026_100628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240122/000124012226000003/form4-06082026_100628.xml","form_type":"4"}},{"id":746142,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24592,"kind":"person","name":"Carruthers R Michael","position":1,"cik":"0001644467","reported_name":"Carruthers R Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:23:33.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001644467-26-000001","document":"form4-06082026_100629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644467/000164446726000001/form4-06082026_100629.xml","form_type":"4"}},{"id":815640,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-03T19:29:11.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":330000,"derivative":{"exercise_price":4.07,"expiration_date":"2036-03-31","underlying":"Class A Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001609284-26-000002","document":"form4-04032026_070404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000002/form4-04032026_070404.xml","form_type":"4"}},{"id":816430,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-03T19:27:44.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":110000,"derivative":{"exercise_price":4.07,"expiration_date":"2036-03-31","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001692747-26-000002","document":"form4-04032026_070438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000002/form4-04032026_070438.xml","form_type":"4"}},{"id":817131,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24691,"kind":"person","name":"Hartley Dylan","position":1,"cik":"0002037442","reported_name":"Hartley Dylan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-03T19:26:27.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":110000,"derivative":{"exercise_price":4.07,"expiration_date":"2036-03-31","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0002037442-26-000001","document":"form4-04032026_070422.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037442/000203744226000001/form4-04032026_070422.xml","form_type":"4"}},{"id":816550,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-03T19:25:25.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":110000,"derivative":{"exercise_price":4.07,"expiration_date":"2036-03-31","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001748961-26-000001","document":"form4-04032026_070420.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000001/form4-04032026_070420.xml","form_type":"4"}},{"id":822561,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-01T21:25:43.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on April 30, 2026 and on the last day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":4.14,"expiration_date":"2036-03-30","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001547100-26-000003","document":"form4-04012026_090435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000154710026000003/form4-04012026_090435.xml","form_type":"4"}},{"id":828987,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2026-03-24T22:57:58.000Z","date":"2026-03-23","kind":"sale","planned":false,"acquired":false,"shares":86,"price":4.1565,"value":357.459,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":7333,"source":{"system":"sec-edgar","filing":"0001609284-26-000001","document":"form4-03242026_100353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928426000001/form4-03242026_100353.xml","form_type":"4"}},{"id":829353,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-24T22:56:09.000Z","date":"2026-03-23","kind":"sale","planned":false,"acquired":false,"shares":301,"price":4.1565,"value":1251.1065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001692747-26-000001","document":"form4-03242026_100303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274726000001/form4-03242026_100303.xml","form_type":"4"}},{"id":954985,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-01-02T21:16:56.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":3911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":15310,"source":{"system":"sec-edgar","filing":"0001193125-26-000942","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526000942/ownership.xml","form_type":"4"}},{"id":955174,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-01-02T21:10:23.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":5258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":20583,"source":{"system":"sec-edgar","filing":"0001622769-26-000001","document":"form4-01022026_090120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276926000001/form4-01022026_090120.xml","form_type":"4"}},{"id":959350,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-12-24T01:09:47.000Z","date":"2025-12-22","kind":"sale","planned":false,"acquired":false,"shares":87,"price":2.9677,"value":258.1899,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025."}],"balance_after":7419,"source":{"system":"sec-edgar","filing":"0001609284-25-000004","document":"form4-12242025_011243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928425000004/form4-12242025_011243.xml","form_type":"4"}},{"id":959662,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-24T01:08:38.000Z","date":"2025-12-22","kind":"sale","planned":false,"acquired":false,"shares":302,"price":2.9677,"value":896.2454,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025."}],"balance_after":16301,"source":{"system":"sec-edgar","filing":"0001692747-25-000004","document":"form4-12242025_011233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274725000004/form4-12242025_011233.xml","form_type":"4"}},{"id":1026631,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-10-02T20:29:28.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":11399,"source":{"system":"sec-edgar","filing":"0001193125-25-228402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312525228402/ownership.xml","form_type":"4"}},{"id":1027171,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-10-02T20:16:25.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":5545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":15325,"source":{"system":"sec-edgar","filing":"0001622769-25-000003","document":"form4-10022025_081020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000162276925000003/form4-10022025_081020.xml","form_type":"4"}},{"id":1032839,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-09-24T23:42:17.000Z","date":"2025-09-22","kind":"sale","planned":false,"acquired":false,"shares":88,"price":2.6235,"value":230.868,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":3506,"source":{"system":"sec-edgar","filing":"0001609284-25-000003","document":"form4-09242025_110912.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000160928425000003/form4-09242025_110912.xml","form_type":"4"}},{"id":1033064,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2025-09-24T23:41:18.000Z","date":"2025-09-22","kind":"sale","planned":false,"acquired":false,"shares":303,"price":2.6235,"value":794.9205,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":12603,"source":{"system":"sec-edgar","filing":"0001692747-25-000003","document":"form4-09242025_110914.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000169274725000003/form4-09242025_110914.xml","form_type":"4"}},{"id":1094556,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-07-02T20:33:22.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":4694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":7274,"source":{"system":"sec-edgar","filing":"0000950170-25-093063","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025093063/ownership.xml","form_type":"4"}},{"id":1095129,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-07-02T20:26:16.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":6311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":9780,"source":{"system":"sec-edgar","filing":"0001415889-25-019052","document":"form4-07022025_080710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588925019052/form4-07022025_080710.xml","form_type":"4"}},{"id":1101501,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-06-25T22:52:16.000Z","date":"2025-06-23","kind":"sale","planned":false,"acquired":false,"shares":88,"price":2.3842,"value":209.8096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001415889-25-018235","document":"form4-06252025_100613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925018235/form4-06252025_100613.xml","form_type":"4"}},{"id":1101706,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2025-06-25T22:49:39.000Z","date":"2025-06-23","kind":"sale","planned":false,"acquired":false,"shares":303,"price":2.3842,"value":722.4126,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":12906,"source":{"system":"sec-edgar","filing":"0001415889-25-018234","document":"form4-06252025_100636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588925018234/form4-06252025_100636.xml","form_type":"4"}},{"id":1128996,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T21:05:33.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000950170-25-079841","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025079841/ownership.xml","form_type":"4"}},{"id":1128879,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:54:43.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001415889-25-015019","document":"form4-05302025_080528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000141588925015019/form4-05302025_080528.xml","form_type":"4"}},{"id":1129210,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:53:31.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001415889-25-015018","document":"form4-05302025_080518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588925015018/form4-05302025_080518.xml","form_type":"4"}},{"id":1129481,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24651,"kind":"person","name":"Jansen Valerie Malyvanh","position":1,"cik":"0001889716","reported_name":"Jansen Valerie Malyvanh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:52:32.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001415889-25-015016","document":"form4-05302025_080515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1889716/000141588925015016/form4-05302025_080515.xml","form_type":"4"}},{"id":1129062,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:51:23.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001415889-25-015015","document":"form4-05302025_080510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240122/000141588925015015/form4-05302025_080510.xml","form_type":"4"}},{"id":1129212,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24592,"kind":"person","name":"Carruthers R Michael","position":1,"cik":"0001644467","reported_name":"Carruthers R Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:50:10.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001415889-25-015014","document":"form4-05302025_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644467/000141588925015014/form4-05302025_080501.xml","form_type":"4"}},{"id":1142937,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":6,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Common Stock","published_at":"2025-05-19T21:33:06.000Z","date":"2025-05-15","kind":"sale","planned":false,"acquired":false,"shares":1813439,"price":1.8545,"value":3363022.6255,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of Class A Common Stock (the \"shares\") sold in a series of open market transactions on the transaction date ranging from $1.85 to $2.03 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000929638-25-001950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825001950/form4.xml","form_type":"4"}},{"id":1142935,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":79603,"kind":"organization","name":"ACORN BIOVENTURES, L.P.","position":1,"cik":"0001766853","reported_name":"ACORN BIOVENTURES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79604,"kind":"organization","name":"ACORN CAPITAL ADVISORS GP, LLC","position":2,"cik":"0001813692","reported_name":"ACORN CAPITAL ADVISORS GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79605,"kind":"person","name":"Hove Anders D","position":3,"cik":"0001365618","reported_name":"Hove Anders D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T16:43:34.000Z","date":"2025-05-15","kind":"purchase","planned":false,"acquired":true,"shares":1129730,"price":1.85,"value":2090000.5,"ownership":{"direct":false,"nature":"By Acorn Bioventures 2, L.P."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held directly by Acorn Bioventures 2, L.P. (\"Acorn 2\"). Acorn Capital Advisors GP 2, LLC (\"Acorn GP 2\") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1129730,"source":{"system":"sec-edgar","filing":"0000950170-25-074459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813692/000095017025074459/ownership.xml","form_type":"4"}},{"id":1142934,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":79603,"kind":"organization","name":"ACORN BIOVENTURES, L.P.","position":1,"cik":"0001766853","reported_name":"ACORN BIOVENTURES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79604,"kind":"organization","name":"ACORN CAPITAL ADVISORS GP, LLC","position":2,"cik":"0001813692","reported_name":"ACORN CAPITAL ADVISORS GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79605,"kind":"person","name":"Hove Anders D","position":3,"cik":"0001365618","reported_name":"Hove Anders D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T16:43:34.000Z","date":"2025-05-15","kind":"purchase","planned":false,"acquired":true,"shares":270270,"price":1.85,"value":499999.5,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares held directly by Acorn Bioventures, L.P. (\"Acorn\"). Acorn Capital Advisors GP, LLC (\"Acorn GP\") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1709944,"source":{"system":"sec-edgar","filing":"0000950170-25-074459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813692/000095017025074459/ownership.xml","form_type":"4"}},{"id":1149321,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"ten_percent_owner":true}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":6,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2025-05-14T20:36:04.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":24300,"price":1.985,"value":48235.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents (i) 429,934 shares of Class A Common Stock beneficially owned by the Master Fund, (ii) 1,099,451 shares of Class A Common Stock beneficially owned by Fund III, (iii) 234,125 shares of Class A Common Stock beneficially owned by Fund IV, and (iv) 49,929 shares of Class A Common Stock beneficially owned by Fund V."}],"balance_after":1813439,"source":{"system":"sec-edgar","filing":"0000929638-25-001870","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825001870/form4.xml","form_type":"4"}},{"id":1175212,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-04-08T21:32:14.000Z","date":"2025-04-07","kind":"sale","planned":false,"acquired":false,"shares":516,"price":2.671,"value":1378.236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":3682,"source":{"system":"sec-edgar","filing":"0001415889-25-010419","document":"form4-04082025_090410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925010419/form4-04082025_090410.xml","form_type":"4"}},{"id":1175211,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2025-04-08T21:32:14.000Z","date":"2025-04-04","kind":"sale","planned":false,"acquired":false,"shares":358,"price":3.3276,"value":1191.2808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":4198,"source":{"system":"sec-edgar","filing":"0001415889-25-010419","document":"form4-04082025_090410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925010419/form4-04082025_090410.xml","form_type":"4"}},{"id":1175629,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2025-04-08T21:30:50.000Z","date":"2025-04-07","kind":"sale","planned":false,"acquired":false,"shares":1844,"price":2.671,"value":4925.324,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":13209,"source":{"system":"sec-edgar","filing":"0001415889-25-010418","document":"form4-04082025_090445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588925010418/form4-04082025_090445.xml","form_type":"4"}},{"id":1175628,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2025-04-08T21:30:50.000Z","date":"2025-04-04","kind":"sale","planned":false,"acquired":false,"shares":1278,"price":3.3276,"value":4252.6728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":15053,"source":{"system":"sec-edgar","filing":"0001415889-25-010418","document":"form4-04082025_090445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588925010418/form4-04082025_090445.xml","form_type":"4"}},{"id":1182841,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-04-02T20:48:28.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":2580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":2580,"source":{"system":"sec-edgar","filing":"0000950170-25-049473","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025049473/ownership.xml","form_type":"4"}},{"id":1183361,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-04-02T20:37:48.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":3469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":3469,"source":{"system":"sec-edgar","filing":"0001415889-25-009659","document":"form4-04022025_080441.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588925009659/form4-04022025_080441.xml","form_type":"4"}},{"id":1291658,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-30T01:36:23.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":130000,"derivative":{"exercise_price":5.19,"expiration_date":"2035-01-26","underlying":"Class A Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-002312","document":"form4-01302025_010119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588925002312/form4-01302025_010119.xml","form_type":"4"}},{"id":1291841,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-30T01:35:11.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":65000,"derivative":{"exercise_price":5.19,"expiration_date":"2035-01-26","underlying":"Class A Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001415889-25-002311","document":"form4-01302025_010107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588925002311/form4-01302025_010107.xml","form_type":"4"}},{"id":1292046,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24691,"kind":"person","name":"Hartley Dylan","position":1,"cik":"0002037442","reported_name":"Hartley Dylan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-30T01:33:56.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":45000,"derivative":{"exercise_price":5.19,"expiration_date":"2035-01-26","underlying":"Class A Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-002310","document":"form4-01302025_010153.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037442/000141588925002310/form4-01302025_010153.xml","form_type":"4"}},{"id":1291877,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-30T01:33:11.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":45000,"derivative":{"exercise_price":5.19,"expiration_date":"2035-01-26","underlying":"Class A Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-002309","document":"form4-01302025_010108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000141588925002309/form4-01302025_010108.xml","form_type":"4"}},{"id":1388525,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"other":true,"other_text":"Former 10% owner of RPHM"}}],"security":"Common Stock","published_at":"2024-10-09T15:25:07.000Z","date":"2024-10-07","kind":"other","planned":false,"acquired":true,"shares":102076,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10.  On October 4, 2024 (the \"Closing Date\"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company (\"Reneo\"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub I\"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub II\"), and OnKure, Inc., a Delaware corporation (\"Legacy OnKure\")."}],"balance_after":102076,"source":{"system":"sec-edgar","filing":"0001373604-24-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000100/form4.xml","form_type":"4"}},{"id":1388524,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"other":true,"other_text":"Former 10% owner of RPHM"}}],"security":"Common Stock","published_at":"2024-10-09T15:25:07.000Z","date":"2024-10-07","kind":"other","planned":false,"acquired":true,"shares":345739,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10.  On October 4, 2024 (the \"Closing Date\"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company (\"Reneo\"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub I\"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub II\"), and OnKure, Inc., a Delaware corporation (\"Legacy OnKure\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":345739,"source":{"system":"sec-edgar","filing":"0001373604-24-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000100/form4.xml","form_type":"4"}},{"id":1389074,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":542232,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":542232,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":542232},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389073,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":8449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":8449,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":8449},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389072,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":16898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":16898,"derivative":{"exercise_price":13.99,"expiration_date":"2033-10-14","underlying":"Class A Common Stock","underlying_shares":16898},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389071,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":1485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":1485,"derivative":{"exercise_price":13.99,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":1485},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389070,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":2359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/12th of the shares subject to the option vested on March 31, 2022 and 1/12th of the shares subject to the option vest on the last day of each quarter thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":2359,"derivative":{"exercise_price":21.2,"expiration_date":"2032-01-10","underlying":"Class A Common Stock","underlying_shares":2359},"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389069,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24488,"kind":"person","name":"Saccomano Nicholas A","position":1,"cik":"0001609284","reported_name":"Saccomano Nicholas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2024-10-08T23:29:45.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":4556,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a \"Service-Based Requirement\" and a \"Liquidity Event Plus Service Requirement.\" 1/16th of the RSUs met the \"Service-Based\" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo Pharmaceuticals, Inc. (\"Reneo\"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo (\"Merger Sub I\"), and OnKure, Inc. (\"OnKure\"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the \"Merger\"). After completion of the Merger, the combined company was renamed \"OnKure Therapeutics, Inc.\" and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol \"OKUR.\""},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a \"Service-Based Requirement\" and a \"Liquidity Event Plus Service Requirement.\" 1/16th of the RSUs met the \"Service-Based\" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo Pharmaceuticals, Inc. (\"Reneo\"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo (\"Merger Sub I\"), and OnKure, Inc. (\"OnKure\"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the \"Merger\"). After completion of the Merger, the combined company was renamed \"OnKure Therapeutics, Inc.\" and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol \"OKUR.\""}],"balance_after":4556,"source":{"system":"sec-edgar","filing":"0001415889-24-024921","document":"form4-10082024_111041.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609284/000141588924024921/form4-10082024_111041.xml","form_type":"4"}},{"id":1389042,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24482,"kind":"person","name":"Phillips Andrew John","position":1,"cik":"0001921956","reported_name":"Phillips Andrew John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-08T23:28:32.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001415889-24-024920","document":"form4-10082024_111029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000141588924024920/form4-10082024_111029.xml","form_type":"4"}},{"id":1389179,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-08T23:27:58.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0000950170-24-113604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024113604/ownership.xml","form_type":"4"}},{"id":1389278,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-08T23:27:36.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001415889-24-024919","document":"form4-10082024_111032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000141588924024919/form4-10082024_111032.xml","form_type":"4"}},{"id":1389338,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:26:39.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":130611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":130611,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":130611},"source":{"system":"sec-edgar","filing":"0001415889-24-024918","document":"form4-10082024_111036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588924024918/form4-10082024_111036.xml","form_type":"4"}},{"id":1389337,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:26:39.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":5322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":5322,"derivative":{"exercise_price":13.99,"expiration_date":"2033-08-29","underlying":"Class A Common Stock","underlying_shares":5322},"source":{"system":"sec-edgar","filing":"0001415889-24-024918","document":"form4-10082024_111036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588924024918/form4-10082024_111036.xml","form_type":"4"}},{"id":1389336,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:26:39.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":5781,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares subject to the option vested on January 3, 2023 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":5781,"derivative":{"exercise_price":21.2,"expiration_date":"2032-01-10","underlying":"Class A Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001415889-24-024918","document":"form4-10082024_111036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588924024918/form4-10082024_111036.xml","form_type":"4"}},{"id":1389335,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24613,"kind":"person","name":"Leverone Jason A.","position":1,"cik":"0001692747","reported_name":"Leverone Jason A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2024-10-08T23:26:39.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":16331,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a \"Service-Based Requirement\" and a \"Liquidity Event Plus Service Requirement.\" 1/16th of the RSUs met the \"Service-Based\" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))"},{"field":"shares","element":"transactionShares","label":"F2","text":"(continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo Pharmaceuticals, Inc. (\"Reneo\"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo (\"Merger Sub I\"), and OnKure, Inc. (\"OnKure\"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the \"Merger\"). After completion of the Merger, the combined company was renamed \"OnKure Therapeutics, Inc.\" and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol \"OKUR.\""},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a \"Service-Based Requirement\" and a \"Liquidity Event Plus Service Requirement.\" 1/16th of the RSUs met the \"Service-Based\" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181st day following the closing of the Merger (as defined below), subject to the Reporting Person continuing as a service provider through such date. On October 4, 2024, the effective time of the Merger, each RSU of OnKure (as defined below) (footnote continued in footnote (2))"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote (1)) was assumed by, and converted into an RSU award of, Reneo (as defined below) covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). The Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo Pharmaceuticals, Inc. (\"Reneo\"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo (\"Merger Sub I\"), and OnKure, Inc. (\"OnKure\"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the \"Merger\"). After completion of the Merger, the combined company was renamed \"OnKure Therapeutics, Inc.\" and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol \"OKUR.\""}],"balance_after":16331,"source":{"system":"sec-edgar","filing":"0001415889-24-024918","document":"form4-10082024_111036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692747/000141588924024918/form4-10082024_111036.xml","form_type":"4"}},{"id":1389432,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24651,"kind":"person","name":"Jansen Valerie Malyvanh","position":1,"cik":"0001889716","reported_name":"Jansen Valerie Malyvanh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-08T23:25:38.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001415889-24-024917","document":"form4-10082024_111035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1889716/000141588924024917/form4-10082024_111035.xml","form_type":"4"}}],"next_cursor":"2024-10-08T23:25:38.000000Z,1389432"}